Search

Displaying results 1761 - 1770 of 4575 in total
  1. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  2. Drug

    Ferric pyrophosphate

    go.drugbank.com/drugs/DB09147
    ApprovedInvestigational

    The ferric ion is strongly complexed by pyrophosphate.[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.

  3. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in...

  4. Drug

    Meperidine

    go.drugbank.com/drugs/DB00454
    ApprovedInvestigational

    A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more...

  5. Drug

    Tolazoline

    go.drugbank.com/drugs/DB00797
    ApprovedVet approvedWithdrawn

    Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear.

  6. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

  7. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying

  8. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63932] Wockhardt announced FDA approval of the cefepime-zidebactam combination on May 30, 2026, for adults with complicated urinary tract infections, including pyelonephritis, caused by designated

  9. Drug

    Mirtazapine

    go.drugbank.com/drugs/DB00370
    ApprovedInvestigational

    [A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. … It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.[A177811]

  10. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.